Antibiotic Reaction, Bone and Joint Infection
Conditions
Keywords
bone and joint infection, prosthesis joint infection, adverse event, ceftaroline, ceftobiprole
Brief summary
Staphyloccous aureus and coagulase negative staphylocci are responsible of a large marjority of PJI. Regarding the high rate of methicillin resistance, current guidelines recommend the use of a glycopeptide, and most frequently vancomycin, as the anti-gram positive agent in empirical therapy, while awaiting the microbiological results. Vancomycin is not considered as a safe antibiotic, and daptomycin is frequently an alternative option. Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. As some data report a synergistic activity with daptomycin, they could be an option in pandrug-resistant staphylococci BJI, but their use if off label in this indication.
Interventions
OTHERDescription of use of ceftaroline and ceftobiprole
Ceftaroline and ceftobiprole are the only betalactam active on methicillin-resistant staphylococci. Description of condition of use of thoses antibiotics in PJI and BJI
Sponsors
Hospices Civils de Lyon
Study design
Observational model
COHORT
Time perspective
RETROSPECTIVE
Eligibility
Sex/Gender
ALL
Age
18 Years to No maximum
Inclusion criteria
* patients having had a PJI or BJI treated whith ceftaroline and/or ceftobiprole
Exclusion criteria
\-
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| rate of failure under ceftobiprole | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
| Evaluation of use of ceftaroline and ceftobiprole : patients | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | type of patients: age, CMI |
| Evaluation of use of ceftaroline: dosage | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | dosage,duration |
| Evaluation of use of ceftaroline : PJI/BJI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | description of the PJI/BJI treated by ceftaroline : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection |
| Evaluation of use of ceftobiprole: dosage | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | dosage, duration |
| Evaluation of use of ceftobiprole: PJI/BJI | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | description of the PJI/BJI treated by ceftobiprole : presence of knee or hip prosthesis, evolution between prosthesis placement and the onset of symptoms, gateway to infection |
| rate of failure under ceftaroline | Outcome is measured at the end of follow-up (usually between 12 and 24 months after antibiotic therapy disruption) | Treatment failure is defined by local clinical and/or microbiological relapse; and/or need for additional surgery; death of septic origin |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Treatment-related adverse events | 2 months | description of adverse event under ceftaroline and/or ceftobiprole as assessed by CTCAE v4.0 |
Countries
France
Outcome results
None listed